Gilenya and Aubagio: A Comparison of MS Treatments

Multiple sclerosis (MS) is a chronic autoimmune disease that attacks the central nervous system, leading to inflammation, nerve damage, and a wide range of symptoms such as fatigue, muscle weakness, and vision problems. While there is no cure for MS, disease-modifying therapies (DMTs) play a crucial role in slowing disease progression, reducing relapses, and improving quality of life.

Among the most commonly prescribed DMTs are Gilenya (fingolimod) and Aubagio (teriflunomide). Both 

gilenya vs aubagio medications belong to different drug classes and work in distinct ways to manage MS. Understanding their mechanisms, efficacy, side effects, and suitability can help patients and healthcare providers make informed decisions.

How Gilenya Works

Gilenya, also known by its generic name fingolimod, is a sphingosine-1-phosphate receptor modulator. It works by trapping certain white blood cells (lymphocytes) in the lymph nodes, preventing them from crossing the blood-brain barrier and attacking the nervous system. This reduces inflammation and damage to the myelin sheath, the protective covering of nerve fibers.

• Administration: Gilenya is taken orally as a capsule, once daily.
• Onset of Action: It begins working within hours of the first dose, though full benefits may take several months to become apparent.
• Efficacy: Clinical trials have shown Gilenya to be highly effective in reducing relapses and slowing disability progression in relapsing-remitting MS (RRMS).

Gilenya is often recommended for patients with active RRMS who have not responded well to other treatments or need a highly effective therapy.

How Aubagio Works

Aubagio, or teriflunomide, belongs to a class of medications called pyrimidine synthesis inhibitors. It works by reducing the activity of immune cells (lymphocytes) that contribute to inflammation and nerve damage in MS. Unlike Gilenya, Aubagio does not trap lymphocytes in the lymph nodes but instead limits their proliferation.

• Administration: Aubagio is taken orally as a tablet, once daily.
• Onset of Action: It may take several weeks to months to show its full effects.
• Efficacy: Aubagio has been shown to reduce relapses and slow disability progression, though its effects are generally considered moderate compared to Gilenya.

Aubagio is often a preferred choice for patients who:

• Prefer a once-daily oral medication.
• Have mild to moderate RRMS.
• Are looking for a lower-risk option with fewer monitoring requirements.

Comparing Efficacy and Safety

When choosing between Gilenya and Aubagio, efficacy and safety are critical factors to consider.

Efficacy

• Gilenya:
  • Superior in reducing relapses (by about 50-60% in clinical trials).
  • Slows disability progression more effectively.
  • MRI scans often show reduced brain lesion activity.
• Aubagio:
  • Reduces relapses by about 30-35%.
  • Moderate effect on disability progression.
  • Less impact on MRI lesion activity compared to Gilenya.

Gilenya is generally considered more potent and is often reserved for patients with more active or aggressive MS.

Safety

• Gilenya:
  • Common side effects: Headache, diarrhea, back pain, and flu-like symptoms.
  • Serious risks: Bradycardia (slow heart rate), especially after the first dose; increased risk of infections; macular edema (swelling in the retina); and liver enzyme elevations.
  • Monitoring: Requires regular blood tests, eye exams, and heart monitoring (especially after the first dose).
• Aubagio:
  • Common side effects: Hair thinning, diarrhea, nausea, and elevated liver enzymes.
  • Serious risks: Liver toxicity and teratogenicity (risk of birth defects if taken during pregnancy).
  • Monitoring: Requires regular liver function tests and birth control for women of childbearing age.

Both medications require baseline and periodic monitoring, but Gilenya’s heart-related risks necessitate closer supervision, especially during the initial phase.

Who Should Consider Gilenya or Aubagio?

Gilenya May Be Suitable For:

• Patients with highly active RRMS.
• Those who need rapid and robust disease control.
• Individuals who have not responded to other DMTs.
• Patients willing to undergo regular monitoring for side effects.

Aubagio May Be Suitable For:

• Patients with mild to moderate RRMS.
• Those who prefer a lower-risk oral medication.
• Individuals who cannot tolerate Gilenya’s side effects or monitoring requirements.
• Patients looking for a convenient once-daily option with less frequent monitoring.

Cost and Accessibility

• Gilenya: Generally more expensive, with costs varying based on insurance coverage. Some patients may qualify for patient assistance programs.
• Aubagio: Often more affordable, with generic versions available in some regions. Insurance coverage is typically more accessible.

Both medications are widely available in most countries, but insurance approval may depend on the patient’s specific MS condition and prior treatments.

Patient Experiences and Preferences

Patient experiences with Gilenya and Aubagio can vary significantly:

• Gilenya users often report rapid symptom improvement and fewer relapses, but some struggle with side effects like bradycardia or infections.
• Aubagio users appreciate its milder side effect profile and convenience, though some find its effectiveness less noticeable compared to Gilenya.

Ultimately, individual tolerance and response play a significant role in determining which medication is the best fit.

Making the Right Choice

Choosing between Gilenya and Aubagio depends on several factors:

1. Disease Activity: Gilenya is preferred for more aggressive MS, while Aubagio may suffice for milder cases.
2. Side Effect Tolerance: Patients prone to infections or heart issues may lean toward Aubagio, while those needing stronger efficacy might choose Gilenya.
3. Lifestyle and Convenience: Aubagio’s once-daily oral form and less frequent monitoring may appeal to some, while others may prioritize Gilenya’s potency.
4. Cost and Insurance: Insurance coverage and out-of-pocket costs can influence the decision.

Final Thoughts

Both Gilenya and Aubagio are valuable options in the management of relapsing-remitting multiple sclerosis. While Gilenya offers superior efficacy, it comes with higher risks and monitoring requirements. Aubagio, on the other hand, provides a safer, more convenient alternative for patients with less aggressive MS.

The best choice depends on individual patient needs, disease characteristics, and lifestyle preferences. A detailed discussion with a neurologist is essential to determine the most suitable treatment plan.